These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29900741)

  • 1. Sweet syndrome after treatment with vedolizumab in a patient with Crohn's disease.
    Martínez Andrés B; Sastre Lozano V; Sánchez Melgarejo JF
    Rev Esp Enferm Dig; 2018 Aug; 110(8):530. PubMed ID: 29900741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
    BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rare Case of Azathioprine-Induced Sweet's Syndrome in a Patient with Crohn's Disease.
    Ben Salem C; Larif S; Fathallah N; Slim R; Aounallah A; Sakhri J; Hmouda H
    Curr Drug Saf; 2015; 10(3):266-8. PubMed ID: 26219289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.
    Gold SL; Magro C; Scherl E
    Gastroenterology; 2018 Oct; 155(4):981-982. PubMed ID: 29614303
    [No Abstract]   [Full Text] [Related]  

  • 7. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
    McLean LP; Cross RK
    Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab in the treatment of Crohn's disease.
    Tarabar D; Hirsch A; Rubin DT
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
    Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
    Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.
    Conrad MA; Stein RE; Maxwell EC; Albenberg L; Baldassano RN; Dawany N; Grossman AB; Mamula P; Piccoli DA; Kelsen JR
    Inflamm Bowel Dis; 2016 Oct; 22(10):2425-31. PubMed ID: 27598742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.
    Pouldar D; Elsensohn A; Ortenzio F; Shiu J; McLeod M; de Feraudy S
    Am J Dermatopathol; 2018 Mar; 40(3):e36-e37. PubMed ID: 28953016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab for Crohn's disease.
    Mosli MH; Feagan BG
    Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach.
    Zargar AA
    Drug Dev Res; 2024 Jun; 85(4):e22220. PubMed ID: 38845229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crohn's disease with anorectal stenosis successfully treated with vedolizumab.
    Urlep D; Orel R
    World J Pediatr; 2017 Aug; 13(4):394-395. PubMed ID: 28540693
    [No Abstract]   [Full Text] [Related]  

  • 20. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease.
    Boland BS; Dulai PS; Chang M; Sandborn WJ; Levesque BG
    Am J Gastroenterol; 2015 Nov; 110(11):1631-2. PubMed ID: 26618431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.